Picture [LSUS] – The Business Web Portal 600x60px
Document › Details

Nanobiotix. (4/24/12). "Press Release: Nanobiotix Appoints Bernd Mühlenweg as a Member of the Executive Board". Paris.

Organisations Organisation Nanobiotix S.A. (Euronext Paris: NANO)
  Group Nanobiotix (Group)
  Organisation 2 Wilex AG
  Today Heidelberg Pharma AG (FSE: WL6)
  Group Heidelberg Pharma (Group)
Products Product nanobiotechnology
  Product 2 oncology
Person Person Mühlenweg, Bernd (Nanobiotix 2011– Head Business Development before 2001–2011 Head BusDev at Wilex AG)

Nanobiotix, a company developing novel cancer nanotherapeutics, today announced it has appointed Dr. Bernd Muehlenweg, currently "Head of Business Development" as a member of the Executive Board in support of the future growth of Nanobiotix.

"Bernd's expertise and experience with business development over the past twelve years and his involvement in the biotech and pharma industry added a lot of value to Nanobiotix during his tenure with us," said Dr. Laurent Levy, CEO and co-founder of Nanobiotix. "I very much look forward to working with him as we continue to further develop and validate our NanoXray product pipeline and to grow Nanobiotix."

Bernd Mühlenweg joined Nanobiotix in 2011 as Head of Business Development. From 2001 to 2011, he had been Director Business Development of oncology company WILEX AG (Munich, Germany), where he played a key role in the negotiation and execution of several license and commercialization agreements with pharma companies and in alliance management. He is a member of the Pharma Licensing Club of Germany (Pharmalizenzclub) and of the Pharma Licensing Club France.


Nanobiotix is a Paris, France, based nanomedicine company dedicated to the development of new cancer treatments. The company combines the advantages of nanotechnology and biotechnology. Nanobiotix is a spin-off of the State University of New York at Buffalo and was incorporated in 2003. It is funded by leading European venture capital firms (Matignon Technologies, OTC Asset Management, Cap Decisif, Amorcage Rhone-Alpes, CM-CIC Capital Innovation and MasseranGestion - CGE). With the development of several new compounds, Nanobiotix's objective is to enhance its leading position in the nanomedicine field.

Nanobiotix Contact

Press Contact
Dr. Laurent Levy, CEO

Ludger Weß/Ines-Regina Buth
+49 40 88 16 59 64
+49 30 23 63 27 68

Record changed: 2015-08-27


Picture [LSA] – The Business Web Portal 650x89px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture EBD Group BIO-Europe 2019 Partnering Report BEU2019 650x80px

» top